{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T06:49:52Z","timestamp":1766472592562,"version":"3.48.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,22]]},"DOI":"10.7759\/cureus.99891","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T06:45:51Z","timestamp":1766472351000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparative Evaluation of the Effects of Oral Anti-hyperglycemic Agents and an Ayurvedic Hepatoprotective Agent in a Rat Model of Non-alcoholic Fatty Liver Disease (NAFLD)"],"prefix":"10.7759","author":[{"given":"S. Shamsher  S","family":"Kalra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Balakrishnan","family":"Sadasivam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Najmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jai K","family":"Chaurasia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi ZM","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023, 77:1335-47. 10.1097\/HEP.0000000000000004","journal-title":"Hepatology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2015.11.008","article-title":"Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"65","author":"Brown GT","year":"2016","unstructured":"Brown GT, Kleiner DE. Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Metabolism. 2016, 65:1080-6. 10.1016\/j.metabol.2015.11.008","journal-title":"Metabolism"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2024.103","article-title":"No more NAFLD: the term is now MASLD","volume":"39","author":"Bae JC","year":"2024","unstructured":"Bae JC. No more NAFLD: the term is now MASLD. Endocrinol Metab (Seoul). 2024, 39:92-4. 10.3803\/EnM.2024.103","journal-title":"Endocrinol Metab (Seoul)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i27.2974","article-title":"Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: from \"two hit theory\" to \"multiple hit model\"","volume":"24","author":"Fang YL","year":"2018","unstructured":"Fang YL, Chen H, Wang CL, Liang L. Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: from \"two hit theory\" to \"multiple hit model\". World J Gastroenterol. 2018, 24:2974-83. 10.3748\/wjg.v24.i27.2974","journal-title":"World J Gastroenterol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i26.8364","article-title":"Experimental models of non-alcoholic fatty liver disease in rats","volume":"20","author":"Kucera O","year":"2014","unstructured":"Kucera O, Cervinkova Z. Experimental models of non-alcoholic fatty liver disease in rats. World J Gastroenterol. 2014, 20:8364-76. 10.3748\/wjg.v20.i26.8364","journal-title":"World J Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","unstructured":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024, 81.492-542. 10.1016\/j.jhep.2024.04.031","journal-title":"J Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00509","article-title":"Role of natural phenolics in hepatoprotection: a mechanistic review and analysis of regulatory network of associated genes","volume":"10","author":"Saha P","year":"2019","unstructured":"Saha P, Talukdar AD, Nath R, Sarker SD, Nahar L, Sahu J, Choudhury MD. Role of natural phenolics in hepatoprotection: a mechanistic review and analysis of regulatory network of associated genes. Front Pharmacol. 2019, 10:509. 10.3389\/fphar.2019.00509","journal-title":"Front Pharmacol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-2049","article-title":"Comparison of tofogliflozin and glimepiride effects on nonalcoholic fatty liver disease in participants with type 2 diabetes: a randomized, 48-week, open-label, active-controlled trial","volume":"45","author":"Takeshita Y","year":"2022","unstructured":"Takeshita Y, Honda M, Harada K, et al.. Comparison of tofogliflozin and glimepiride effects on nonalcoholic fatty liver disease in participants with type 2 diabetes: a randomized, 48-week, open-label, active-controlled trial. Diabetes Care. 2022, 45:2064-75. 10.2337\/dc21-2049","journal-title":"Diabetes Care"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S393816","article-title":"Chemical chaperones to inhibit endoplasmic reticulum stress: implications in diseases","volume":"16","author":"Jeon JH","year":"2022","unstructured":"Jeon JH, Im S, Kim HS, Lee D, Jeong K, Ku JM, Nam TG. Chemical chaperones to inhibit endoplasmic reticulum stress: implications in diseases. Drug Des Devel Ther. 2022, 16:4385-97. 10.2147\/DDDT.S393816","journal-title":"Drug Des Devel Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.934136","article-title":"Dapagliflozin protects against nonalcoholic steatohepatitis in db\/db mice","volume":"13","author":"Qiao P","year":"2022","unstructured":"Qiao P, Jia Y, Ma A, et al.. Dapagliflozin protects against nonalcoholic steatohepatitis in db\/db mice. Front Pharmacol. 2022, 13:934136. 10.3389\/fphar.2022.934136","journal-title":"Front Pharmacol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24127","article-title":"Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings","volume":"53","author":"Brunt EM","year":"2011","unstructured":"Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 2011, 53:810-20. 10.1002\/hep.24127","journal-title":"Hepatology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.21315\/mjms2017.24.5.11","article-title":"Sample size calculation in animal studies using resource equation approach","volume":"24","author":"Arifin WN","year":"2017","unstructured":"Arifin WN, Zahiruddin WM. Sample size calculation in animal studies using resource equation approach. Malays J Med Sci. 2017, 24:101-5. 10.21315\/mjms2017.24.5.11","journal-title":"Malays J Med Sci"},{"key":"ref13","doi-asserted-by":"crossref","DOI":"10.1007\/s00580-011-1372-7","article-title":"Reference values for the serum lipid profile of albino rats (Rattus norvegicus) of varied ages and sexes","volume":"22","author":"Ihedioha JI","year":"2013","unstructured":"Ihedioha JI, Noel-Uneke OA, Ihedioha TE. Reference values for the serum lipid profile of albino rats (Rattus norvegicus) of varied ages and sexes. Comp Clin Pathol. 2013, 22:93-9.","journal-title":"Comp Clin Pathol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1258\/002367798780599802","article-title":"Reference database of the main physiological parameters in Sprague-Dawley rats from 6 to 32 months","volume":"32","author":"Alem\u00e1n CL","year":"1998","unstructured":"Alem\u00e1n CL, M\u00e1s RM, Rodeiro I, Noa M, Hern\u00e1ndez C, Men\u00e9ndez R, G\u00e1mez R. Reference database of the main physiological parameters in Sprague-Dawley rats from 6 to 32 months. Lab Anim. 1998, 32:457-66. 10.1258\/002367798780599802","journal-title":"Lab Anim"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3109\/08941939.2011.586094","article-title":"Type of steatosis influences microcirculation and fibrogenesis in different rat strains","volume":"24","author":"Rosenstengel S","year":"2011","unstructured":"Rosenstengel S, Stoeppeler S, Bahde R, Spiegel HU, Palmes D. Type of steatosis influences microcirculation and fibrogenesis in different rat strains. J Invest Surg. 2011, 24:273-82. 10.3109\/08941939.2011.586094","journal-title":"J Invest Surg"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1177\/0023677212473717","article-title":"Gender and strain-specific differences in the development of steatosis in rats","volume":"47","author":"St\u00f6ppeler S","year":"2013","unstructured":"St\u00f6ppeler S, Palmes D, Fehr M, et al.. Gender and strain-specific differences in the development of steatosis in rats. Lab Anim. 2013, 47:43-52. 10.1177\/0023677212473717","journal-title":"Lab Anim"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23063131","article-title":"A novel Sprague-Dawley rat model presents improved NASH\/NAFLD symptoms with PEG coated vitexin liposomes","volume":"23","author":"Farooq A","year":"2022","unstructured":"Farooq A, Iqbal A, Rana NF, et al.. A novel Sprague-Dawley rat model presents improved NASH\/NAFLD symptoms with PEG coated vitexin liposomes. Int J Mol Sci. 2022, 23:3131. 10.3390\/ijms23063131","journal-title":"Int J Mol Sci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0194867","article-title":"Chronic calcitriol supplementation improves the inflammatory profiles of circulating monocytes and the associated intestinal\/adipose tissue alteration in a diet-induced steatohepatitis rat model","volume":"13","author":"Su YB","year":"2018","unstructured":"Su YB, Li TH, Huang CC, et al.. Chronic calcitriol supplementation improves the inflammatory profiles of circulating monocytes and the associated intestinal\/adipose tissue alteration in a diet-induced steatohepatitis rat model. PLoS One. 2018, 13:e0194867. 10.1371\/journal.pone.0194867","journal-title":"PLoS One"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13279","article-title":"Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, open-label, three-arm, active control study","volume":"11","author":"Kinoshita T","year":"2020","unstructured":"Kinoshita T, Shimoda M, Nakashima K, et al.. Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, open-label, three-arm, active control study. J Diabetes Investig. 2020, 11:1612-22. 10.1111\/jdi.13279","journal-title":"J Diabetes Investig"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.5114\/aoms\/161228","article-title":"Comparison of glimepiride and linagliptin in the treatment of non-alcoholic hepatic disease with type 2 diabetes mellitus","volume":"20","author":"Tian F","year":"2024","unstructured":"Tian F, Guo Y, Zhou L, et al.. Comparison of glimepiride and linagliptin in the treatment of non-alcoholic hepatic disease with type 2 diabetes mellitus. Arch Med Sci. 2024, 20:1407-15. 10.5114\/aoms\/161228","journal-title":"Arch Med Sci"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1590\/1806-9282.65.1.33","article-title":"The efficacy of saxagliptin in T2DM patients with non-alcoholic fatty liver disease: preliminary data","volume":"65","author":"Li JJ","year":"2019","unstructured":"Li JJ, Zhang P, Fan B, Guo XL, Zheng ZS. The efficacy of saxagliptin in T2DM patients with non-alcoholic fatty liver disease: preliminary data. Rev Assoc Med Bras (1992). 2019, 65:33-7. 10.1590\/1806-9282.65.1.33","journal-title":"Rev Assoc Med Bras (1992)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.4103\/0253-7613.125166","article-title":"Combination of vildagliptin and rosiglitazone ameliorates nonalcoholic fatty liver disease in C57BL\/6 mice","volume":"46","author":"Mookkan J","year":"2014","unstructured":"Mookkan J, De S, Shetty P, et al.. Combination of vildagliptin and rosiglitazone ameliorates nonalcoholic fatty liver disease in C57BL\/6 mice. Indian J Pharmacol. 2014, 46:46-50. 10.4103\/0253-7613.125166","journal-title":"Indian J Pharmacol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.12669\/pjms.326.11133","article-title":"Vildagliptin ameliorates biochemical, metabolic and fatty changes associated with non alcoholic fatty liver disease","volume":"32","author":"Hussain M","year":"2016","unstructured":"Hussain M, Majeed Babar MZ, Hussain MS, Akhtar L. Vildagliptin ameliorates biochemical, metabolic and fatty changes associated with non alcoholic fatty liver disease. Pak J Med Sci. 2016, 32:1396-401. 10.12669\/pjms.326.11133","journal-title":"Pak J Med Sci"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15958","article-title":"The impact of vildagliptin as an add-on therapy on matrix metalloproteinase-14 levels, liver stiffness and subclinical atherosclerosis in adolescents with type 1 diabetes and non-alcoholic steatohepatitis: a randomized controlled trial","volume":"26","author":"ElKabbany ZA","year":"2024","unstructured":"ElKabbany ZA, Ismail EA, Hamed ET, Elbarbary NS. The impact of vildagliptin as an add-on therapy on matrix metalloproteinase-14 levels, liver stiffness and subclinical atherosclerosis in adolescents with type 1 diabetes and non-alcoholic steatohepatitis: a randomized controlled trial. Diabetes Obes Metab. 2024, 26:5857-69. 10.1111\/dom.15958","journal-title":"Diabetes Obes Metab"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3892\/br.2024.1904","article-title":"Dapagliflozin treatment alleviates fatty liver in patients with type 2 diabetes","volume":"22","author":"Gao X","year":"2025","unstructured":"Gao X, Zhu C, Zhu W, Wang L. Dapagliflozin treatment alleviates fatty liver in patients with type 2 diabetes. Biomed Rep. 2025, 22:26. 10.3892\/br.2024.1904","journal-title":"Biomed Rep"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202309_33570","article-title":"Effect of dapagliflozin against NAFLD and dyslipidemia in type 2 diabetic albino rats: possible underlying mechanisms","volume":"27","author":"Said Ahmed WM","year":"2023","unstructured":"Said Ahmed WM, Soliman A, Ahmed Amer AE, et al.. Effect of dapagliflozin against NAFLD and dyslipidemia in type 2 diabetic albino rats: possible underlying mechanisms. Eur Rev Med Pharmacol Sci. 2023, 27:8101-9. 10.26355\/eurrev_202309_33570","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.5603\/EP.a2023.0018","article-title":"Sodium glucose cotransporter-2-inhibitor dapagliflozin improves nonalcoholic fatty liver disease by ameliorating dipeptidyl-peptidase-4 protein expression in diabetic mice","volume":"74","author":"Zhao DM","year":"2023","unstructured":"Zhao DM, Li CQ, Sun YM, Fan JY, Wu N, Sun YN, Sun XY. Sodium glucose cotransporter-2-inhibitor dapagliflozin improves nonalcoholic fatty liver disease by ameliorating dipeptidyl-peptidase-4 protein expression in diabetic mice. Endokrynol Pol. 2023, 74:190-6. 10.5603\/EP.a2023.0018","journal-title":"Endokrynol Pol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13457","article-title":"Favorable effect of sodium-glucose cotransporter\u00a02 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone","volume":"12","author":"Cho KY","year":"2021","unstructured":"Cho KY, Nakamura A, Omori K, et al.. Favorable effect of sodium-glucose cotransporter\u00a02 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone. J Diabetes Investig. 2021, 12:1272-7. 10.1111\/jdi.13457","journal-title":"J Diabetes Investig"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.589273","article-title":"Dapagliflozin alleviates hepatic steatosis by restoring autophagy via the AMPK-mTOR pathway","volume":"12","author":"Li L","year":"2021","unstructured":"Li L, Li Q, Huang W, et al.. Dapagliflozin alleviates hepatic steatosis by restoring autophagy via the AMPK-mTOR pathway. Front Pharmacol. 2021, 12:589273. 10.3389\/fphar.2021.589273","journal-title":"Front Pharmacol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.14974","article-title":"Effect of dapagliflozin on type 2 diabetes mellitus with nonalcoholic fatty liver disease: a single-center survey","volume":"13","author":"Das C","year":"2021","unstructured":"Das C, Tripathy D, Swain S, Sudhakaran N, Uthansingh K, Mallick P, Pati GK. Effect of dapagliflozin on type 2 diabetes mellitus with nonalcoholic fatty liver disease: a single-center survey. Cureus. 2021, 13:e14974. 10.7759\/cureus.14974","journal-title":"Cureus"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3164\/jcbn.20-129","article-title":"Comparison of dapagliflozin and teneligliptin in nonalcoholic fatty liver disease patients without type 2 diabetes mellitus: a prospective randomized study","volume":"68","author":"Tobita H","year":"2021","unstructured":"Tobita H, Yazaki T, Kataoka M, et al.. Comparison of dapagliflozin and teneligliptin in nonalcoholic fatty liver disease patients without type 2 diabetes mellitus: a prospective randomized study. J Clin Biochem Nutr. 2021, 68:173-80. 10.3164\/jcbn.20-129","journal-title":"J Clin Biochem Nutr"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13907","article-title":"Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes","volume":"22","author":"Gastaldelli A","year":"2020","unstructured":"Gastaldelli A, Repetto E, Guja C, Hardy E, Han J, Jabbour SA, Ferrannini E. Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes. Diabetes Obes Metab. 2020, 22:393-403. 10.1111\/dom.13907","journal-title":"Diabetes Obes Metab"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-019-00785-6","article-title":"Effect of sodium glucose co-transporter 2 inhibitors on liver fat mass\u00a0and body composition in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus","volume":"39","author":"Arase Y","year":"2019","unstructured":"Arase Y, Shiraishi K, Anzai K, et al.. Effect of sodium glucose co-transporter 2 inhibitors on liver fat mass\u00a0and body composition in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus. Clin Drug Investig. 2019, 39:631-41. 10.1007\/s40261-019-00785-6","journal-title":"Clin Drug Investig"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4675-2","article-title":"Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study","volume":"61","author":"Eriksson JW","year":"2018","unstructured":"Eriksson JW, Lundkvist P, Jansson PA, et al.. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia. 2018, 61:1923-34. 10.1007\/s00125-018-4675-2","journal-title":"Diabetologia"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhazmat.2024.135234","article-title":"Enhanced thorium decorporation and mitigation of toxicity through combined use of Liv52\u00ae and diethylenetriamine pentaacetate","volume":"477","author":"Ali M","year":"2024","unstructured":"Ali M, Kumar Das S, Shetake NG, Pandey BN, Kumar A. Enhanced thorium decorporation and mitigation of toxicity through combined use of Liv52\u00ae and diethylenetriamine pentaacetate. J Hazard Mater. 2024, 477:135234. 10.1016\/j.jhazmat.2024.135234","journal-title":"J Hazard Mater"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1080\/10520295.2022.2065533","article-title":"Ameliorative effects of Liv-52 on doxorubicin-induced oxidative damage in rat liver","volume":"97","author":"Yildirim N","year":"2022","unstructured":"Yildirim N, Lale A, Yaz\u0131c\u0131 GN, et al.. Ameliorative effects of Liv-52 on doxorubicin-induced oxidative damage in rat liver. Biotech Histochem. 2022, 97:616-21. 10.1080\/10520295.2022.2065533","journal-title":"Biotech Histochem"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-019-0380-0","article-title":"The effect of Liv-52 on liver ischemia reperfusion damage in rats","volume":"21","author":"Cimen O","year":"2020","unstructured":"Cimen O, Eken H, Keskin Cimen F, et al.. The effect of Liv-52 on liver ischemia reperfusion damage in rats. BMC Pharmacol Toxicol. 2020, 21:2. 10.1186\/s40360-019-0380-0","journal-title":"BMC Pharmacol Toxicol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3923\/pjbs.2019.299.308","article-title":"Protective role of Carissa edulis ethanolic extract against dimethoate-induced hepatotoxicity in guinea pigs","volume":"22","author":"Al-Awthan YS","year":"2019","unstructured":"Al-Awthan YS, Salem Bahattab O. Protective role of Carissa edulis ethanolic extract against dimethoate-induced hepatotoxicity in guinea pigs. Pak J Biol Sci. 2019, 22:299-308. 10.3923\/pjbs.2019.299.308","journal-title":"Pak J Biol Sci"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.etp.2016.12.005","article-title":"Protective effect of Tritone (Livosone) on oxidative DNA damage and its hepatoprotective potential against various hepatotoxic agent in Wistar rats","volume":"69","author":"Medhekar SK","year":"2017","unstructured":"Medhekar SK, Jadhav TP, Sasane VS, et al.. Protective effect of Tritone (Livosone) on oxidative DNA damage and its hepatoprotective potential against various hepatotoxic agent in Wistar rats. Exp Toxicol Pathol. 2017, 69:153-61. 10.1016\/j.etp.2016.12.005","journal-title":"Exp Toxicol Pathol"},{"key":"ref40","article-title":"A clinical comparative study to evaluate the efficacy and safety of LIV.52 DS tablets in non-alcoholic steatohepatitis (NASH)","volume":"4","author":"Maity SG","year":"2015","unstructured":"Maity SG, Mandal AK. A clinical comparative study to evaluate the efficacy and safety of LIV.52 DS tablets in non-alcoholic steatohepatitis (NASH). World J Pharm Res. 2015, 4:398-414.","journal-title":"World J Pharm Res"},{"key":"ref41","article-title":"Evaluation of safety and efficacy of a polyherbal formulation Liv.52 DS in the management of non-alcoholic steatohepatitis (NASH): an open clinical study","volume":"2","author":"Ghosh S","year":"2014","unstructured":"Ghosh S, Singh DP, Mandal KD, Kumar S. Evaluation of safety and efficacy of a polyherbal formulation Liv.52 DS in the management of non-alcoholic steatohepatitis (NASH): an open clinical study. Int J Curr Res Acad Rev. 2014, 2:305-16.","journal-title":"Int J Curr Res Acad Rev"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi K","year":"2016","unstructured":"Cusi K, Orsak B, Bril F, et al.. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med. 2016, 165:305-15. 10.7326\/M15-1774","journal-title":"Ann Intern Med"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.06.047","article-title":"Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis","volume":"135","author":"Aithal GP","year":"2008","unstructured":"Aithal GP, Thomas JA, Kaye PV, et al.. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 2008, 135:1176-84. 10.1053\/j.gastro.2008.06.047","journal-title":"Gastroenterology"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal AJ","year":"2010","unstructured":"Sanyal AJ, Chalasani N, Kowdley KV, et al.. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010, 362:1675-85. 10.1056\/NEJMoa0907929","journal-title":"N Engl J Med"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort R","year":"2006","unstructured":"Belfort R, Harrison SA, Brown K, et al.. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006, 355:2297-307. 10.1056\/NEJMoa060326","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/448113-comparative-evaluation-of-the-effects-of-oral-anti-hyperglycemic-agents-and-an-ayurvedic-hepatoprotective-agent-in-a-rat-model-of-non-alcoholic-fatty-liver-disease-nafld","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T06:45:52Z","timestamp":1766472352000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/448113-comparative-evaluation-of-the-effects-of-oral-anti-hyperglycemic-agents-and-an-ayurvedic-hepatoprotective-agent-in-a-rat-model-of-non-alcoholic-fatty-liver-disease-nafld"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":45,"URL":"https:\/\/doi.org\/10.7759\/cureus.99891","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,22]]}}}